10.1371/journal.pone.0049418 126 LiuM.LiangK.ZhenJ.ZhouM.WangX.WangZ.et al (2017)
Subcutaneous semaglutide, on the other hand, was more frequently used to replace a previous regimen including an insulin (prandial or basal or both), compared with oral semaglutide (10.2% and 4.2% of cases, respectively), but the difference did not reach statistical significance
Conclusions A 90-day L-carnitine therapy in patients with nonalcoholic steatohepatitis and obesity improves clinical symptoms, reduces liver markers (ALT by 3.3 times, AST by 3.0 times), decreases cholestasis markers (-glutamyltransferase by 2.2 times, ALP by 2.06 times), and reduces mesenchymal inflammation (thymol test by 3.3 times)
Great final point Sebastian
I really cannot say enough about Michelle